ArticleProceedings of the National Academy of Sciences of the United States of America1994
Antisense oligonucleotides adsorbed to polyalkylcyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 169 citations in OpenAlex.
- Defining Endocytic Pathways of Fucoidan-Coated PIBCA Nanoparticles from the Design of their Surface Architecture.Pharmaceutical research · 2022Article
- Emerging Applications of Nanotechnology in Healthcare Systems: Grand Challenges and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement.Biomolecules · 2020Review
- Small GTPases: Structure, biological function and its interaction with nanoparticles.Asian journal of pharmaceutical sciences · 2019Review
- Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting.BioMed research international · 2014Article
- Nanocarriers' entry into the cell: relevance to drug delivery.Cellular and molecular life sciences : CMLS · 2009Review
- Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.British journal of pharmacology · 2009Review
- Nanotechnology: intelligent design to treat complex disease.Pharmaceutical research · 2006Review
- Innovations in oligonucleotide drug delivery.Journal of pharmaceutical sciences · 2003Review
- The use of synthetic polymers for delivery of therapeutic antisense oligodeoxynucleotides.Biomaterials · 2002Review
- The spherulites(TM): a promising carrier for oligonucleotide delivery.Nucleic acids research · 2000Article
- Polyisobutylcyanoacrylate nanocapsules containing an aqueous core as a novel colloidal carrier for the delivery of oligonucleotides.Pharmaceutical research · 2000Article
- Antisense pharmacodynamics: critical issues in the transport and delivery of antisense oligonucleotides.Pharmaceutical research · 1999Review
- Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.Investigational new drugs · 1999Review
- SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression.British journal of cancer · 1998Article
- Oligodeoxynucleotides enhance lipopolysaccharide-stimulated synthesis of tumor necrosis factor: dependence on phosphorothioate modification and reversal by heparin.Molecular medicine (Cambridge, Mass.) · 1996Article
- Pharmacokinetics and biodistribution of oligonucleotide adsorbed onto poly(isobutylcyanoacrylate) nanoparticles after intravenous administration in mice.Pharmaceutical research · 1996Article
- Rational design of point mutation-selective antisense DNA targeted to codon 12 of Ha-ras mRNA in human cells.Nucleic acids research · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ras oncogenes owe their transforming properties to single point mutations in the sequence coding for the active site of the p21 protein. These mutations lead to changes in cellular proliferation and induce tumorigenic properties. Point mutations represent a well-defined target for antisense oligonucleotides that can specifically suppress the translation of the targeted mutant mRNA. We show that the stability and cellular disponibility of antisense oligonucleotides can be markedly improved by adsorption to polyalkylcyanoacrylate nanoparticles. Nanoparticle-adsorbed antisense oligonucleotides directed to a point mutation (G-->U) in codon 12 of the Ha-ras mRNA selectively inhibited the proliferation of cells expressing the point-mutated Ha-ras gene at a concentration 100 times lower than free oligonucleotides. In addition they markedly inhibited Ha-ras-dependent tumor growth in nude mice after subcutaneous injection. These experiments show that inhibition of ras oncogenes by antisense oligonucleotides can block tumor development even though ras oncogenic activation might be an early event in tumor progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.